Clinical trial · no report yet · Phase 2
DeLLphi-309
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
- NCT06745323 ↗
- Active not recruiting
- Amgen
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Tarlatamab
- Arms
- Treatment Arm A: Dose 1 Tarlatamab · Experimental
- Treatment Arm B: Dose 2 Tarlatamab · Experimental
- Treatment Arm C: Dose 3 Tarlatamab · Experimental
- Enrollment
- 252
- Primary outcomes
- Proportion of participants with confirmed objective response to Tarlatamab
- Proportion of participants with complete response to Tarlatamab
- Proportion of participants with partial response to Tarlatamab
- Sponsor
- Amgen
- Start
- Feb 26, 2025
- Primary completion
- Aug 10, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06745323 · updated Oct 6, 2026